Muszytowski M, Manitius J, Ruszkiewicz-Fołda M
Z Ośrodka Dializ Wojewódzkiego, Szpitala Zespolonego w Toruniu.
Przegl Lek. 1996;53(5):417-9.
We have studied the antibody response to hepatitis B vaccine in 42 hemodialysis patients; 8 of them were diagnosed as having HCV infection before vaccination. Hemodialysis patients received four doses of recombinant HB vaccine (Engerix-B, SKB, 40 micrograms per dose). Seroconversion occurred in 71.4% of all hemodialysis patients; in 79.4% of HCV-negative and in 37.5% of HCV-positive patients. Effective immunity (anti-HBs titer higher than 100 m IU/ml) was observed in 12.5% of HCV positive and in 35.3% of HCV-negative patients. We conclude that HCV infection may modify or postpone the response to hepatitis B vaccine.
我们研究了42例血液透析患者对乙型肝炎疫苗的抗体反应；其中8例在接种疫苗前被诊断为丙型肝炎病毒（HCV）感染。血液透析患者接种了四剂重组乙肝疫苗（安在时，史克必成公司生产，每剂40微克）。所有血液透析患者的血清转化率为71.4%；HCV阴性患者的血清转化率为79.4%，HCV阳性患者的血清转化率为37.5%。在HCV阳性患者中有12.5%、HCV阴性患者中有35.3%观察到有效免疫（抗-HBs滴度高于100 mIU/ml）。我们得出结论，HCV感染可能会改变或推迟对乙型肝炎疫苗的反应。
